menu
    • menu
    [{"orgOrder":0,"company":"TargImmune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"TAR001","moa":"EGFR","graph1":"Oncology","graph2":"Preclinical","graph3":"TargImmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TargImmune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"TargImmune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"TargImmune Therapeutics","sponsor":"iOncologi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2025","type":"Acquisition","leadProduct":"TAR001","moa":"EGFR","graph1":"Oncology","graph2":"Preclinical","graph3":"TargImmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TargImmune Therapeutics \/ iOncologi","highestDevelopmentStatusID":"4","companyTruncated":"TargImmune Therapeutics \/ iOncologi"}]

    Find Clinical Drug Pipeline Developments & Deals by TargImmune Therapeutics

    Menu

    TargImmune Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            TargImmune Therapeutics

                            Switzerland arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            TargImmune Therapeutics

                            Switzerland arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TAR001

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : iOncologi

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            iOncologi Acquires TargImmune Therapeutics

                            Details : Through the acquisition, iOncologi will strengthen it's oncology pipeline including TAR001, which is being evaluated preclinical stage for treating neoplasms.

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Undisclosed

                            March 14, 2025

                            Lead Product(s) : TAR001

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : iOncologi

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            TargImmune Therapeutics

                            Switzerland arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            TargImmune Therapeutics

                            Switzerland arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TAR001

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            TargImmune Announces Successful Completion of GLP/Tox Studies and Further Reinforcement of Leadership Team wit...

                            Details : TAR001, targets epidermal growth factor receptors (EGFR). EGFR overexpression is prevalent in a significant proportion of solid cancers and is often associated with more aggressive disease.

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            June 07, 2022

                            Lead Product(s) : TAR001

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth